• Japanese
  • Korean
  • Chinese
Cover Image

Respiratory Partnering Terms and Agreements

The Respiratory Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the respiratory partnering deals and agreements entered into by the worlds leading healthcare companies

Description

The Respiratory Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the respiratory partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter respiratory partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors respiratory technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,000 links to online copies of actual respiratory deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of respiratory dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in respiratory dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading respiratory deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of respiratory deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all respiratory deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all respiratory partnering deals signed and announced since 2009. The chapter is organized by specific respiratory therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all respiratory partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in respiratory partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of respiratory technologies and products.

Benefits

Respiratory Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of respiratory deal trends since 2009
  • Access respiratory deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between respiratory partner companies
  • Comprehensive access to over 1,000 links to actual respiratory deals entered into by the world's biopharma companies
  • Indepth review of respiratory deals entered into by the leading fifty bigpharma companies
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner respiratory opportunities
  • Uncover companies actively partnering respiratory opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in respiratory dealmaking

  • 2.1. Introduction
  • 2.2. Respiratory partnering over the years
  • 2.3. Bigpharma respiratory dealmaking activity
  • 2.4. Bigpharma not active in respiratory
  • 2.5. Respiratory partnering by deal type
  • 2.6. Respiratory partnering by industry sector
  • 2.7. Respiratory partnering by stage of development
  • 2.8. Respiratory partnering by technology type
  • 2.9. Respiratory partnering by respiratory indication
  • 2.10. Average deal terms for respiratory
    • 2.10.1 Respiratory headline values
    • 2.10.2 Respiratory upfront payments
    • 2.10.3 Respiratory milestone payments
    • 2.10.4 Respiratory royalty rates

Chapter 3 - Leading respiratory deals

  • 3.1. Introduction
  • 3.2. Top respiratory deals by value
  • 3.3. Top respiratory deals involving bigpharma

Chapter 4 - Bigpharma respiratory deals

  • 4.1. Introduction
  • 4.2. How to use bigpharma partnering deals
  • 4.3. Bigpharma respiratory partnering company profiles
  • Abbott
  • Actavis
  • Actelion
  • Amgen
  • Aspen Pharmacare
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Dainippon Sumitomo
  • Eisai
  • Eli Lilly
  • Forest Laboratories
  • Gilead Sciences
  • GlaxoSmithKline
  • Hospira
  • Menarini
  • Merck & Co
  • Merck KGaA
  • Mylan
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Shionogi
  • Shire
  • Teva
  • Valeant

Chapter 5 - Respiratory partnering contracts directory

  • 5.1. Introduction
  • 5.2. By deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Contract service
  • Co-promotion
  • Development
  • Distribution
  • Equity purchase
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Settlement
  • Sub-license
  • Supply
  • Termination
  • 5.3. By stage of development
  • Discovery
  • Formulation
  • Marketed
  • Phase I
  • Phase II
  • Phase III
  • Preclinical
  • Regulatory
  • 5.4. By technology type
  • Analysis
  • Assays
  • Biodefense
  • Biological compounds
  • Clinical testing
  • Devices
  • Diagnostics
  • Discovery tools
  • Drug delivery
  • Enabling technology
  • Genomics
  • Industrial chemicals
  • In vitro models
  • Nanotechnology
  • Oligonucleotide
  • Packaging
  • Peptides
  • Processes
  • Proteomics
  • Regenerative medicine
  • RNA therapeutics
  • Screening
  • Small molecules
  • Stem cells
  • Vaccines

Chapter 6 - Respiratory dealmaking by indication

  • 6.1. Introduction
  • 6.2. Deals by therapeutic indication
  • Respiratory
  • Acute respiratory distress syndrome
  • Allergic rhinitis
  • Asthma
  • Bronchitis
  • Chronic obstructive pulmonary disease
  • Emphysema
  • Idiopathic pulmonary fibrosis
  • Pneumonia
  • Pulmonary arterial hypertension
  • Pulmonary embolism
  • Respiratory Tract Infection
  • Sarcoidosis
  • Sinusitis
  • Cough
  • Snoring

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Directory of respiratory deals by company A-Z 2009-2014
  • Appendix 2 - Directory of respiratory deals by deal type 2009-2014
  • Appendix 3 - Directory of respiratory deals by stage of development 2009-2014
  • Appendix 4 - Directory of respiratory deals by technology type 2009-2014
  • Appendix 5 - Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering
  • Order Form - Reports
  • Order Form - Therapy Reports
  • Table of figures
  • Figure 1: Respiratory partnering since 2009
  • Figure 2: Bigpharma - top 50 - respiratory deals 2009 to 2012
  • Figure 3: Bigpharma respiratory deal frequency - 2009 to 2012
  • Figure 4: Inactive bigpharma in respiratory 2009-2014
  • Figure 5: Respiratory partnering by deal type since 2009
  • Figure 6: Respiratory partnering by industry sector since 2009 37
  • Figure 7: Respiratory partnering by stage of development since 2009
  • Figure 8: Respiratory partnering by technology type since 2009
  • Figure 9: Respiratory partnering by respiratory target since 2009
  • Figure 10: Respiratory deals with a headline value
  • Figure 11: Respiratory deal headline value distribution, US$million - discovery stage
  • Figure 12: Respiratory deal headline value distribution, US$million - preclinical stage
  • Figure 13: Respiratory deal headline value distribution, US$million - phase I stage
  • Figure 14: Respiratory deal headline value distribution, US$million - phase II stage
  • Figure 15: Respiratory deal headline value distribution, US$million - phase III stage
  • Figure 16: Respiratory deal headline value distribution, US$million - regulatory stage
  • Figure 17: Respiratory deal headline value distribution, US$million - marketed stage
  • Figure 18: Summary median headline value by stage of development, 2009-2014
  • Figure 19 Respiratory deals with upfront payment values
  • Figure 20: Respiratory deal upfront payment distribution, US$million - discovery stage
  • Figure 21: Respiratory deal upfront payment distribution, US$million - preclinical stage
  • Figure 22: Respiratory deal upfront payment distribution, US$million - phase I stage
  • Figure 23: Respiratory deal upfront payment distribution, US$million - phase II stage
  • Figure 24: Respiratory deal upfront payment distribution, US$million - phase III stage
  • Figure 25: Respiratory deal upfront payment distribution, US$million - regulatory stage
  • Figure 26: Respiratory deal upfront payment distribution, US$million - marketed stage
  • Figure 27: Summary median upfront payments by stage of development, 2009-2014
  • Figure 28: Respiratory deals with milestone payments
  • Figure 29: Respiratory deal milestone distribution, US$million - discovery stage
  • Figure 30: Respiratory deal milestone distribution, US$million - preclinical stage
  • Figure 31: Respiratory deal milestone distribution, US$million - phase I stage
  • Figure 32: Respiratory deal milestone distribution, US$million - phase II stage
  • Figure 33: Respiratory deal milestone distribution, US$million - phase III stage
  • Figure 34: Respiratory deal milestone distribution, US$million - regulatory stage
  • Figure 35: Respiratory deal milestone distribution, US$million - marketed stage
  • Figure 36: Respiratory deals with royalty rates, %
  • Figure 37: Respiratory deal royalty rate distribution, US$million - discovery stage
  • Figure 38: Respiratory deal royalty rate distribution, US$million - preclinical stage
  • Figure 39: Respiratory deal royalty rate distribution, US$million - phase I stage
  • Figure 40: Respiratory deal royalty rate distribution, US$million - phase II stage
  • Figure 41: Respiratory deal royalty rate distribution, US$million - phase III stage
  • Figure 42: Respiratory deal royalty rate distribution, US$million - regulatory stage
  • Figure 44: Summary median royalty rate by stage of development, 2009-2014
  • Figure 45: Top respiratory deals by value since 2009
  • Figure 46: Top respiratory deals signed by bigpharma value since 2009
  • Figure 47: Online partnering resources
  • Figure 48: Forthcoming partnering events
Show More
Pricing